Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Juan

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
ESMO Open|August 30, 2024
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II studyA Rodriguez-Vida, B P Valderrama, D Castellano, et al.
ESMO Real World Data and Digital Oncology|July 1, 2026
First-line osimertinib in advanced <i>EGFR</i>-mutated NSCLC: real-world outcomes, clinicogenomic correlates, and oligoprogression management in a multicenter Spanish cohortG Suay, S Cases-Esteban, P Capdevila, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 26, 2016
A consensus statement on the gender perspective in lung cancerD Isla, M Majem, N Viñolas, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 26, 2018
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patientsJ Garde-Noguera, P Martin-Martorell, M De Julián, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 11, 2018
Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patientsJ Garde-Noguera, P Martin-Martorell, M De Julián, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2018
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotypingJ Zugazagoitia, I Ramos, J M Trigo, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2020
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer GroupJ Remon, E Nadal, M Dómine, et al.
ESMO Open|May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LAD P Carbone, T-E Ciuleanu, M Cobo, et al.
ESMO Open|December 5, 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]M Reck, T-E Ciuleanu, M Cobo, et al.
ESMO Open|October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year updateM Reck, T-E Ciuleanu, M Cobo, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
ESMO Open|August 30, 2024
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II studyA Rodriguez-Vida, B P Valderrama, D Castellano, et al.
ESMO Real World Data and Digital Oncology|July 1, 2026
First-line osimertinib in advanced <i>EGFR</i>-mutated NSCLC: real-world outcomes, clinicogenomic correlates, and oligoprogression management in a multicenter Spanish cohortG Suay, S Cases-Esteban, P Capdevila, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 26, 2016
A consensus statement on the gender perspective in lung cancerD Isla, M Majem, N Viñolas, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 26, 2018
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patientsJ Garde-Noguera, P Martin-Martorell, M De Julián, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 11, 2018
Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patientsJ Garde-Noguera, P Martin-Martorell, M De Julián, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2018
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotypingJ Zugazagoitia, I Ramos, J M Trigo, et al.
Lung Cancer (Amsterdam, Netherlands)|July 19, 2020
Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer GroupJ Remon, E Nadal, M Dómine, et al.
ESMO Open|May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LAD P Carbone, T-E Ciuleanu, M Cobo, et al.
ESMO Open|December 5, 2021
Corrigendum to 'First-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus chemotherapy alone (4 cycles) in advanced non-small cell lung cancer: CheckMate 9LA 2-year update': [ESMO Open Volume 6, Issue 5, October 2021, 100273]M Reck, T-E Ciuleanu, M Cobo, et al.
ESMO Open|October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year updateM Reck, T-E Ciuleanu, M Cobo, et al.
Pageof 5